Alkermes
artistry in combination with responses in heavily treated ovarian cancer tumor type line of therapy artistry part efficacy ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer evaluation of evaluation of evaluation of evaluation of ongoing out of patients with scans patients experienced an objective response confirmed and unconfirmed patients remain on study as of march data cut time on study weeks intravenous progressive disease partial response stable disease complete response data cut off march alkermes | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
72 of 144
Related slides by other companies
Immatics
Investor Presentation
November 2023
gen melanoma as first indication for pivotal development cohort a | Immatics
Exscientia
Investor Day
January 2024
enabling studies complete | Exscientia
TCR2 Therapeutics
Results
September 2022
patient platinum refractory ovarian cancer | TCR2 Therapeutics
Nuvalent
Investor Presentation
October 2023
resistance mutations induced rapid responses in resistant patients resistant | Nuvalent
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io